Guangxi Medical University
广西医科大学
Hospitals that carry this university's name, added together, plus papers and trials that name only the university.
Research activity, not treatment quality. Not medical advice. How this works
Nasopharyngeal carcinoma
鼻咽癌Led 124 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (23.4%).
- Open trials led
- 8
- Research papers it led
- 124
- Trials it led
- 19
- Share of China's trials
- 3.2%
- Share of the world's papers
- 3.8%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Effect of modified Baduanjin exercise on nutritional status in patients with nasopharyngeal carcinoma: a randomized controlled trial.
- Scheduling radiotherapy for patients with nasopharyngeal carcinoma in the corresponding time window can reduce radiation-induced oral mucositis: A randomized, prospective study.
- The application of the PDCA cycle in the nutritional management of patients with nasopharyngeal carcinoma.
- Maintenance therapy improves the survival outcomes of patients with metastatic nasopharyngeal carcinoma responding to first-line chemotherapy: a multicentre, randomized controlled clinical study.
- Association of Epstein-Barr virus DNA and SAA with S1 maintenance therapy outcomes in patients with metastatic nasopharyngeal carcinoma.
Trials on ClinicalTrials.gov6
- Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC
- Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma
- Impacted Tooth Management and Osteoradionecrosis Risk in NPC
- Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma
- Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy
- Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma
Oesophageal squamous cell carcinoma
食管鳞状细胞癌Led 8 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (6.9%).
- Open trials led
- 0
- Research papers it led
- 8
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.2%
Over half of these papers are lab or animal studies.
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- The predictors of lymphopenia and its effects on survival in locally advanced esophageal squamous cell carcinoma.
- Adjuvant treatment patterns for pT3N0M0 esophageal cancer undergoing surgery.
- Immune checkpoint inhibitors combined with concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.
- Overexpression of UBE2C in esophageal squamous cell carcinoma tissues and molecular analysis.
- Macrophage Infiltration and ITGB2 Expression in ESCC: A Novel Correlation.
Trials on ClinicalTrials.gov6
- SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
- A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
- A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
- Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma
- Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
- A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma
Hepatocellular carcinoma
肝细胞癌Led 378 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (5.5%).
- Open trials led
- 4
- Research papers it led
- 378
- Trials it led
- 29
- Share of China's trials
- 2.0%
- Share of the world's papers
- 1.3%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Radiotherapy is superior to transarterial chemoembolization as adjuvant therapy after narrow-margin hepatectomy in patients with hepatocellular carcinoma: A single-center prospective randomized study.
- Nomogram based on clinical and preoperative CT features for predicting the early recurrence of combined hepatocellular-cholangiocarcinoma: a multicenter study.
- Nomograms for postsurgical extrahepatic recurrence prediction of hepatocellular carcinoma based on presurgical circulating tumor cell status and clinicopathological factors.
- Efficacy comparison of optimal treatments for hepatocellular carcinoma patients with portal vein tumor thrombus.
- Prognostic value of a nomogram based on peripheral blood immune parameters in unresectable hepatocellular carcinoma after intensity-modulated radiotherapy.
Trials on ClinicalTrials.gov6
- Adjuvant TACE in HCC With High-risk Recurrence Factors
- Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC
- Adjuvant Immune Checkpoint Inhibitors in Postoperative Hepatocellular Carcinoma
- Conversion or Neoadjuvant Therapy in Hepatocellular Carcinoma
- A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
- The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study
Stomach cancer
胃癌Led 68 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (3.9%).
- Open trials led
- 1
- Research papers it led
- 68
- Trials it led
- 2
- Share of China's trials
- 0.1%
- Share of the world's papers
- 0.3%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- SOX combined with intraperitoneal perfusion of docetaxel compared with DOS regimen in the first-line therapy for advanced gastric cancer with malignant ascites: a prospective observation.
- Neoadjuvant Docetaxel, Oxaliplatin, and S-1 in Resectable Advanced Gastric Cancer.
- Body Composition Decrease and Impact on Clinical Outcome in Gastric Cancer Patients Undergoing Radical Gastrectomy After Neoadjuvant Treatment.
- Integrating visceral protein ratios and mid-arm circumference predicts survival and malnutrition in gastric cancer.
- Prognostic significance of anthropometric measurements in gastric cancer: a multicenter cohort study.
Trials on ClinicalTrials.gov6
- Stomach-Partitioning Versus Conventional Gastrojejunostomy for Malignant Gastric Outlet Obstruction: A Multicenter Randomized Controlled Trial
- Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
- A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
- A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
Hepatoblastoma
肝母细胞瘤Led 2 of 154 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (13.6%).
- Open trials led
- 0
- Research papers it led
- 2
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.4%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Osteosarcoma
骨肉瘤Led 51 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (4.3%).
- Open trials led
- 0
- Research papers it led
- 51
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 1.0%
Over half of these papers are lab or animal studies.
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Clinical model of pulmonary metastasis in patients with osteosarcoma: A new multiple machine learning-based risk prediction.
- Prognostic significance of T cells and NK cells in osteosarcoma: a dual-center retrospective study.
- A Case of Non-calcified Intrahepatic Primary Osteosarcoma: A Case Report and a Literature Review.
- A new model of preoperative systemic inflammatory markers predicting overall survival of osteosarcoma: a multicenter retrospective study.
- Prognostic value of preoperative P-CRP in patients with osteosarcoma: A retrospective study of 101 cases.
Gastrointestinal stromal tumour
胃肠道间质瘤Led 0 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (6.3%).
- Open trials led
- 0
- Research papers it led
- 0
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.0%
Neuroblastoma
神经母细胞瘤Led 4 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (8.8%).
- Open trials led
- 0
- Research papers it led
- 4
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.09%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led4
- Computed tomography-guided microwave ablation therapy for pediatric adrenal neuroblastoma with lung nodule a case report.
- MLKL regulates Cx43 ubiquitinational degradation and mediates neuronal necroptosis in ipsilateral thalamus after focal cortical infarction.
- Inhibition of ERK downregulates autophagy via mitigating mitochondrial fragmentation to protect SH-SY5Y cells from OGD/R injury.
- Competing endogenous RNA network analysis of the molecular mechanisms of ischemic stroke.
Ewing sarcoma
尤文肉瘤Led 4 of 163 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (8.6%).
- Open trials led
- 0
- Research papers it led
- 4
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.4%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led4
- Ablation of EWS-FLI1 by USP9X inhibition suppresses cancer cell growth in Ewing sarcoma.
- Novel prognostic biomarkers, METTL14 and YTHDF2, associated with RNA methylation in Ewing's sarcoma.
- Glycolysis- and immune-related novel prognostic biomarkers of Ewing's sarcoma: glucuronic acid epimerase and triosephosphate isomerase 1.
- CCT6A, a novel prognostic biomarker for Ewing sarcoma.
Multiple myeloma
多发性骨髓瘤Led 11 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (4.8%).
- Open trials led
- 0
- Research papers it led
- 11
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.1%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Active Epstein-Barr virus infection and its association with multiple myeloma: evidence from a meta-analytical perspective.
- Beyond ISS staging: the prognostic value of the Inflammation Prognostic Score Index (IPSI) in multiple myeloma.
- Correlation analysis of laboratory indicators, genetic abnormalities and staging in patients with newly diagnosed multiple myeloma.
- Autologous followed by allogeneic versus tandem-autologous transplantation in high-risk, newly diagnosed multiple myeloma: a systematic review and meta-analysis.
- Expression and Clinical Significance of BCL2 Interacting Protein 3 Like in Multiple Myeloma.
Trials on ClinicalTrials.gov6
- Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
- A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
- A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
Haemophagocytic lymphohistiocytosis (HLH)
噬血细胞性淋巴组织细胞增生症Led 3 of 399 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (22.3%).
- Open trials led
- 0
- Research papers it led
- 3
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led3
- Sintilimab combined with chidamide in the treatment of extranodal nature killer/T-cell lymphoma with secondary hemophagocytic lymphohistiocytosis: Two case reports and literature review.
- Intrathoracic infections in Hodgkin lymphoma (HL) patients may cooperate with HL to trigger hemophagocytic lymphohistiocytosis: A retrospective study.
- Intrapleural infections in patients with subcutaneous panniculitis-like T-cell lymphoma are susceptible to hemophagocytic lymphohistiocytosis.
Beta thalassaemia
β 地中海贫血Led 29 of 312 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (9.9%).
- Open trials led
- 1
- Research papers it led
- 29
- Trials it led
- 5
- Share of China's trials
- 10.6%
- Share of the world's papers
- 1.7%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Effects of Thalidomide on Metabolism and Lifespan of Red Blood Cell in Patients With β-Thalassemia Major: A Post Hoc Analysis of a Randomized Controlled Trial.
- Whole-Brain Analysis of Increased Brain Iron in Patients with β-Thalassemia.
- White matter microstructure abnormalities in thalassemia patients using TBSS analysis based on DTI.
- Correlation study between magnetic resonance imaging-quantitated cardiac iron deposition and left ventricular function in patients with β-thalassemia major in China.
- Neuroimaging in the diagnosis and treatment of cerebral toxoplasmosis in children with severe β-thalassemia after allo-HSCT.
Trials on ClinicalTrials.gov6
- A Study Evaluating the Safety and Efficacy of LentiRed Drug Product in Transfusion-dependent β-Thalassemia [TDT]
- A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major
- A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemia
- Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
- A Pilot Study on the Safety and Efficacy of YOLT-204 for Transfusion-Dependent Beta-Thalassemia
- Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical Study
Haemophilia A
血友病 ALed 4 of 272 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (15.8%).
- Open trials led
- 0
- Research papers it led
- 4
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.1%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led4
- Clinical validation and application of targeted long-range polymerase chain reaction and long-read sequencing-based analysis for hemophilia: experience from a hemophilia treatment center in China.
- Spectrum of Factor VIII Gene Variants in 78 Patients with Hemophilia A in Guangxi Province, China, Including Nine Novel Variants: A Descriptive Study.
- Detection of hemophilia A genetic variants using third-generation long-read sequencing.
- The novel mutation p.Asp315Tyr causes severe hemophilia B by impairing coagulation factor IX expression.
Trials on ClinicalTrials.gov5
- Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.
- Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment
- A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A
- Clinical Study of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With Inhibitor
- Safety, Efficacy Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.
Neuromyelitis optica spectrum disorder (NMOSD)
视神经脊髓炎谱系疾病Led 3 of 485 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (10.5%).
- Open trials led
- 0
- Research papers it led
- 3
- Trials it led
- 1
- Share of China's trials
- 1.3%
- Share of the world's papers
- 0.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led3
- A comparative study of hypothalamic involvement in patients with myelin oligodendrocyte glycoprotein antibody-associated disease, neuromyelitis optica spectrum disorder, and multiple sclerosis.
- The impact of COVID-19 on a Southern Chinese cohort with neuromyelitis optica spectrum disorders.
- Recent Advances in Neuromyelitis Optica Spectrum Disorder: Pathogenesis, Mechanisms and Potential Treatments.
Trials on ClinicalTrials.gov1
Myasthenia gravis
重症肌无力Led 6 of 499 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (6.6%).
- Open trials led
- 0
- Research papers it led
- 6
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.3%
Over half of these papers are lab or animal studies.
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- The characteristics of new-onset myasthenia gravis after COVID-19 outbreak: a cross-sectional study.
- Clinical Efficacy and Safety of Eculizumab for Treating Myasthenia Gravis.
- FcRn inhibition with efgartigimod ameliorates muscle weakness and modulates dendritic cell subsets in an experimental autoimmune myasthenia gravis mouse model.
- miR-125a-5p regulates Treg function by targeting Foxp3 in experimental autoimmune myasthenia gravis mice.
- DCAF12 and HSPA1A May Serve as Potential Diagnostic Biomarkers for Myasthenia Gravis.
Moyamoya disease
烟雾病Led 4 of 356 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (19.9%).
- Open trials led
- 0
- Research papers it led
- 4
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.3%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led4
- Association of peripheral blood inflammatory biomarkers and poor clinical outcomes in adult stroke patients with moyamoya disease.
- Bilateral carotid and vertebral rete mirabile with aneurysm misdiagnosed as Moyamoya disease: A case report.
- Efficacy of double-barrel versus single-branch superficial temporal artery-middle cerebral artery bypass in the treatment of moyamoya disease: Does double-barrel bypass offer any advantages?
- Predictive Factors for Seizures after Revascularization in Patients with Moyamoya Disease.
Anti-NMDA receptor encephalitis
抗 NMDA 受体脑炎Led 13 of 264 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (10.2%).
- Open trials led
- 0
- Research papers it led
- 13
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 1.8%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- To analyze the efficacy and safety of plasma exchange in the treatment of anti-NMDA receptor encephalitis.
- Successful treatment with efgartigimod as an add-on therapy for acute attack of anti-NMDA receptor encephalitis: a case report.
- The Clinical Features and Prognosis of Anti-NMDAR Encephalitis Depends on Blood Brain Barrier Integrity.
- Clinical characteristics and long-term prognosis of relapsing anti-N-methyl-D-aspartate receptor encephalitis: a retrospective, multicenter, self-controlled study.
- Elevated Release of Presynaptic Glutamate: The Potential Pathogenesis of Anti-NMDAR Encephalitis-Associated Seizures.
Takayasu arteritis
大动脉炎Led 2 of 187 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (24.6%).
- Open trials led
- 0
- Research papers it led
- 2
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Idiopathic pulmonary fibrosis
特发性肺纤维化Led 4 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (4.3%).
- Open trials led
- 0
- Research papers it led
- 4
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.1%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led4
- Biological and pharmacological roles of pyroptosis in pulmonary inflammation and fibrosis: recent advances and future directions.
- Novel kinase 1 regulates CD8+T cells as a potential therapeutic mechanism for idiopathic pulmonary fibrosis.
- A novel prognostic index based on the analysis of glycolysis-related genes in idiopathic pulmonary fibrosis.
- A Novel 5-Methylcytosine- and Immune-Related Prognostic Signature Is a Potential Marker of Idiopathic Pulmonary Fibrosis.
Trials on ClinicalTrials.gov1
Amyotrophic lateral sclerosis
肌萎缩侧索硬化症Led 2 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (8.3%).
- Open trials led
- 0
- Research papers it led
- 2
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.03%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Duchenne muscular dystrophy
杜氏肌营养不良Led 4 of 213 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (10.8%).
- Open trials led
- 0
- Research papers it led
- 4
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led4
- Clinical Diagnosis and Genetic Analysis of Children With Muscular Dystrophies.
- Histone modifications in Duchenne muscular dystrophy: pathogenesis insights and therapeutic implications.
- The cryptic complex rearrangements involving the DMD gene: etiologic clues about phenotypical differences revealed by optical genome mapping.
- Identification of hub genes related to Duchenne muscular dystrophy by weighted gene co-expression network analysis.
IgA nephropathy
IgA 肾病Led 5 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (9.4%).
- Open trials led
- 0
- Research papers it led
- 5
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.3%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Machine-learning model based on ultrasomics for non-invasive evaluation of fibrosis in IgA nephropathy.
- Correlation analysis of cofilin-1 with renal prognosis in primary IgA nephropathy.
- Characteristics and function of the gut microbiota in patients with IgA nephropathy via metagenomic sequencing technology.
- Expression of GADD45B in Renal Tissue of Children with IgA Nephropathy and Correlation with Mesangial Hypercellularity.
- Metal mixture exposure and the risk for immunoglobulin A nephropathy: Evidence from weighted quantile sum regression.
Trials on ClinicalTrials.gov2
Primary biliary cholangitis
原发性胆汁性胆管炎Led 2 of 300 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (12.0%).
- Open trials led
- 0
- Research papers it led
- 2
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led2
- The clinical value of the monocyte to high-density lipoprotein cholesterol ratio and alkaline phosphatase-to-platelet ratio in primary biliary cholangitis.
- Diagnostic and Prognostic Value of Monocyte-to-Lymphocyte Ratio and Red Cell Distribution Width to Lymphocyte Ratio in Primary Biliary Cholangitis.